Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321456 | 0.89 | CYP11B2 (0.58) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 | |
| SCHEMBL30129588 | 0.89 | CYP11B2 (0.58) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 | |
| SCHEMBL11279823 | 0.80 | MAPK14 (0.41) | CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL679561 | 0.79 | NPC1 (0.47) | ALDH1A1 | |
| SCHEMBL17795989 | 0.76 | CYP11B2 (0.46) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 | |
| SCHEMBL11623647 | 0.76 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 | |
| SCHEMBL11623645 | 0.76 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 | |
| SCHEMBL11623867 | 0.75 | CHRNB2 (0.38) | CYP11B2CHRNB4CHRNA3 | |
| SCHEMBL30919753 | 0.73 | PPARA (0.63) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 | |
| SCHEMBL9082413 | 0.73 | PPARA (0.63) | CYP11B2CYP11B1CYP19A1CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4026900-A | 3-(Pyridinyl)-2-cyclohexen-1-ones | STERLING DRUG INC. (US) | 1977-05-31 | — | — | US | claimed |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2020-04-30 | — | — | US | disclosed |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890139-B2 | CYP17 inhibitors/antiandrogens | ORION CORPORATION (FI) | 2018-02-13 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016085939-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2016-05-12 | — | — | US | disclosed |
| EP-3008042-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | Orion Corporation (FI) | 2016-04-20 | — | — | EP | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-5849764-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0871624-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| US-4127583-A | Preparation of 3-(pyridinyl)-2-cyclohexene-1-ones | STERLING DRUG INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4111946-A | Preparation of 3-(pyridinyl)-2-cyclohexen-1-ones | STERLING DRUG INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4075217-A | Conversion of 3-(pyridinyl)-2-cyclohexen-1-one to 3-(pyridinyl)anilines | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-4026900-A | 3-(Pyridinyl)-2-cyclohexen-1-ones | STERLING DRUG INC. (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | CYP11B2 38/4885CYP11B1 57/4885CYP19A1 646/4885 |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | CYP11B2 50/4885CYP11B1 83/4885CYP19A1 712/4885 |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | CYP11B2 839/4885CYP11B1 713/4885CYP19A1 3112/4885 |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | CYP17A1, CYP19A1, CYP21A2 | CYP11B2 9/4885CYP11B1 6/4885CYP19A1 2/4885 |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | CYP11B2 50/4885CYP11B1 83/4885CYP19A1 712/4885 |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | CYP11B2 38/4885CYP11B1 57/4885CYP19A1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.